Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Small Cell Lung Carcinoma 13Neoplasms 6Breast Neoplasms 3Advanced Solid Tumor 3Sarcoma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors 2Stomach Neoplasms 1Solid Tumors 1Sarcoma, Ewing 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Major Advanced Solid Tumors Other Than Colorectal 1Lung Neoplasms 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Endometrial Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1ADVANCED SOLID TUMORS 1

Interventions

Everolimus 15surufatinib 7lutetium Lu 177 dotatate 6lanreotide 6amino-acid, glucose, and electrolyte solution 5Octreotide 5Sunitinib 4Data Collection 4pasireotide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2pembrolizumab 2fosbretabulin 2arginyllysine 2Temozolomide 2Paclitaxel 2PM 01183 2Irinotecan 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1pelcitoclax 1liposomal doxorubicin 1gadoteridol 1gadoterate meglumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neuroendocrine Tumors × PM 01183 × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

PharmaMar

Phase 1 Completed
122 enrolled 19 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡